CLOVIS Oncology (Seite 102)
eröffnet am 19.12.16 18:46:55 von
neuester Beitrag 14.01.23 11:56:55 von
neuester Beitrag 14.01.23 11:56:55 von
Beiträge: 1.109
ID: 1.243.172
ID: 1.243.172
Aufrufe heute: 0
Gesamt: 53.189
Gesamt: 53.189
Aktive User: 0
ISIN: US1894641000 · WKN: A1JPJY
0,0817
USD
-4,22 %
-0,0036 USD
Letzter Kurs 21.12.22 NYSE
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,8800 | +57,45 | |
| 17,440 | +44,61 | |
| 1,8400 | +26,03 | |
| 4,9500 | +25,32 | |
| 4,0000 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,965 | -18,48 | |
| 0,7845 | -19,36 | |
| 3,3200 | -22,61 | |
| 0,6785 | -26,19 | |
| 3,3100 | -77,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 61.561.575 von 1Fuchschen am 25.09.19 07:47:29Das Problem ist, dass man eben kein Geld verdient und sich am Markt nicht wirklich durchsetzen konnte. Vielleicht wäre eine Übernahme wirklich das Beste, denn ob die mal Geld verdienen, scheint mir sehr fraglich. Die meisten werden bei dieser Aktie im Verlust sein, ich habe bei ungefähr 10 Euro die Reißleine gezogen und kaufe auch jetzt nicht zurück. Das Kapitel ist abgeschlossen.
Antwort auf Beitrag Nr.: 61.568.262 von DomRuinart am 25.09.19 18:58:26Tiefer geht wohl immer noch, ESMO hat wohl auch nichts gebracht
Antwort auf Beitrag Nr.: 61.563.804 von 1Fuchschen am 25.09.19 11:07:07Bin wieder drin, der Kurs ist ein Witz...
schon dramatisch eingebrochen, aber jetzt könnte der Boden erreicht sein.
Ich überlege bald nochmal nachzukaufen, bin mit einer kleinen posi dabei
Ich überlege bald nochmal nachzukaufen, bin mit einer kleinen posi dabei
Wer ist hier noch drin? Also was denkt ihr?
Trading Spotlight
Ich habe irgendwie im Gefühl, dass hier etwas im Busch ist.
Antwort auf Beitrag Nr.: 59.614.634 von questionmark am 12.01.19 08:15:27
Ja vor nicht einmal einem Jahr war das...heute mikrige 4,25 Dollar.
Zitat von questionmark:Zitat von bcgk: Mittlerweile bei 52$ angekommen. MC lediglich 2,6 Mrd $.
Könnte ein Takeover Target sein.....
Jetzt erst recht
Hat aber vom tief schon ordentlich zugelegt.
Jetzt War ja JP Morgan, mal sehen, was der Kurs macht
Ja vor nicht einmal einem Jahr war das...heute mikrige 4,25 Dollar.
Tesaro hatte man damals auch lange geshortet und hatte eine Mk von 600 Mio und wurde dann für 5 Milliarden übernommen. Vielleicht haben die Shortis da auch ihre Hände mit im Spiel.
Antwort auf Beitrag Nr.: 61.558.437 von DomRuinart am 24.09.19 18:53:37
Naja. Der Kurs wird derzeit ja von den Shortis gemacht. 42 Prozent der Aktien ist short. Das heisst es muss bald eine Gegenbewegung kommen. Der Laden ist derzeit knapp über 200 Mio wert. Klar hoher Cash burn allerdings haben die noch 500 Mio cash. Parp inhibitor am Markt, rubraca pipeline groß. Und der Deal ist gar nicht so uninteressant. Vielleicht rührt sich Big Pharma bald und übernimmt clovis endlich für 10-20 Dollar und das Trauerspiel ist zu Ende.
Zitat von DomRuinart: Ja, Analysten stören sich am Zeitpunkt und fürchten, Clovis könnte die Kohle ausgehen...
Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed
By
Josh Nathan-Kazis
Sept. 24, 2019 8:58 am ET
One analyst has run out of patience with Clovis Oncology , a biotech firm that focuses on cancer drugs.
In a note Tuesday morning, SVB Leerink’s Andrew Berens took a hard line on the company’s decision, announced on Monday, to license a targeted radiotherapy program from a private German biotechnology company called 3B Pharmaceuticals.
The deal is “ill-timed given investor concerns about the company’s use of cash and solvency amidst an increasing mountain of convertible debt,” Berens wrote. He downgraded Clovis (ticker: CLVS) to Market Perform from Outperform, and cut his price target to $10 from $22. The stock closed at $4.59 on Monday.
Clovis didn’t immediately respond to a request for comment about the downgrade.
The back story. Shares of Clovis are down 74.5% this year. The company’s drug Rubraca, a so-called PARP inhibitor that treats ovarian cancer, is facing growing competition from offerings from AstraZeneca (AZN) and a GlaxoSmithKline (GSK) subsidiary.
What’s new. In his note, Berens said the deal, under which Clovis made a $12 million upfront payment for the rights to a preclinical radiopharmaceutical program, was a bad sign.
“While the deal to in-license a radiotherapy for [about] $12 [million] up front does not seem exorbitant and could eventually add fundamental value, it burdens Clovis with development expenses and milestones at a time when equity investors are increasingly concerned that the company is not aligned with their best interests,” Berens wrote. “Development of these programs will draw on incremental financial resources at a time when many investors remain concerned about near-term cash flows and solvency of the company.”
He also said that the deal could distract from Rubraca, and said that it suggests that a “near-term acquisition of the company is unlikely.”
His lowered price target remains 118% higher than the Monday closing price, but Berens said “current management strategies are unlikely to unlock this value in the near term.”
Quelle: Dow Jones & Company, Inc
Naja. Der Kurs wird derzeit ja von den Shortis gemacht. 42 Prozent der Aktien ist short. Das heisst es muss bald eine Gegenbewegung kommen. Der Laden ist derzeit knapp über 200 Mio wert. Klar hoher Cash burn allerdings haben die noch 500 Mio cash. Parp inhibitor am Markt, rubraca pipeline groß. Und der Deal ist gar nicht so uninteressant. Vielleicht rührt sich Big Pharma bald und übernimmt clovis endlich für 10-20 Dollar und das Trauerspiel ist zu Ende.
Antwort auf Beitrag Nr.: 61.557.951 von questionmark am 24.09.19 18:06:09Ja, Analysten stören sich am Zeitpunkt und fürchten, Clovis könnte die Kohle ausgehen...
Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed
By
Josh Nathan-Kazis
Sept. 24, 2019 8:58 am ET
One analyst has run out of patience with Clovis Oncology , a biotech firm that focuses on cancer drugs.
In a note Tuesday morning, SVB Leerink’s Andrew Berens took a hard line on the company’s decision, announced on Monday, to license a targeted radiotherapy program from a private German biotechnology company called 3B Pharmaceuticals.
The deal is “ill-timed given investor concerns about the company’s use of cash and solvency amidst an increasing mountain of convertible debt,” Berens wrote. He downgraded Clovis (ticker: CLVS) to Market Perform from Outperform, and cut his price target to $10 from $22. The stock closed at $4.59 on Monday.
Clovis didn’t immediately respond to a request for comment about the downgrade.
The back story. Shares of Clovis are down 74.5% this year. The company’s drug Rubraca, a so-called PARP inhibitor that treats ovarian cancer, is facing growing competition from offerings from AstraZeneca (AZN) and a GlaxoSmithKline (GSK) subsidiary.
What’s new. In his note, Berens said the deal, under which Clovis made a $12 million upfront payment for the rights to a preclinical radiopharmaceutical program, was a bad sign.
“While the deal to in-license a radiotherapy for [about] $12 [million] up front does not seem exorbitant and could eventually add fundamental value, it burdens Clovis with development expenses and milestones at a time when equity investors are increasingly concerned that the company is not aligned with their best interests,” Berens wrote. “Development of these programs will draw on incremental financial resources at a time when many investors remain concerned about near-term cash flows and solvency of the company.”
He also said that the deal could distract from Rubraca, and said that it suggests that a “near-term acquisition of the company is unlikely.”
His lowered price target remains 118% higher than the Monday closing price, but Berens said “current management strategies are unlikely to unlock this value in the near term.”
Quelle: Dow Jones & Company, Inc
Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed
By
Josh Nathan-Kazis
Sept. 24, 2019 8:58 am ET
One analyst has run out of patience with Clovis Oncology , a biotech firm that focuses on cancer drugs.
In a note Tuesday morning, SVB Leerink’s Andrew Berens took a hard line on the company’s decision, announced on Monday, to license a targeted radiotherapy program from a private German biotechnology company called 3B Pharmaceuticals.
The deal is “ill-timed given investor concerns about the company’s use of cash and solvency amidst an increasing mountain of convertible debt,” Berens wrote. He downgraded Clovis (ticker: CLVS) to Market Perform from Outperform, and cut his price target to $10 from $22. The stock closed at $4.59 on Monday.
Clovis didn’t immediately respond to a request for comment about the downgrade.
The back story. Shares of Clovis are down 74.5% this year. The company’s drug Rubraca, a so-called PARP inhibitor that treats ovarian cancer, is facing growing competition from offerings from AstraZeneca (AZN) and a GlaxoSmithKline (GSK) subsidiary.
What’s new. In his note, Berens said the deal, under which Clovis made a $12 million upfront payment for the rights to a preclinical radiopharmaceutical program, was a bad sign.
“While the deal to in-license a radiotherapy for [about] $12 [million] up front does not seem exorbitant and could eventually add fundamental value, it burdens Clovis with development expenses and milestones at a time when equity investors are increasingly concerned that the company is not aligned with their best interests,” Berens wrote. “Development of these programs will draw on incremental financial resources at a time when many investors remain concerned about near-term cash flows and solvency of the company.”
He also said that the deal could distract from Rubraca, and said that it suggests that a “near-term acquisition of the company is unlikely.”
His lowered price target remains 118% higher than the Monday closing price, but Berens said “current management strategies are unlikely to unlock this value in the near term.”
Quelle: Dow Jones & Company, Inc
Durchsuchen
